Clinical Study | Office of Clinical Research

Nrg-Hn004- Randomized Phase II/III Trial Of Radiotherapy With Concurrent Medi4736 (Durvalumab) Vs. Radiotherapy With Concurrent Cetuximab In Patients With Stage III-Ivb Head And Neck Cancer With A Contraindication To Cisplatin

Posted Date: May 15, 2019

Investigator: Vinita Takiar
Specialties: Cancer, Head and Neck Cancer, Oncology
Type of Study: Drug

To determine the safety and effectiveness of radiotherapy (RT) with concurrent and adjuvant anti-PD-L1 therapy [MEDI4736 (durvalumab)] is safe in patients with locoregionally advanced head and neck cancer (HNC) who have a contraindication to cisplatin.

Criteria:

To Be Eligible: Must Have Diagnosed Advanced Hnscc With Contraindiction To Cisplatin, Must Be 18 Years Or Older, Bodyweight >30Kg, No Prior Malignancy In <3 Years

Keywords:

Head And Neck Cancer, Phase Ii/Iii

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List